Capricor Therapeutics (CAPR) Tops Q3 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.59 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating